Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor

NCT06556862 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

155

Enrollment

OTHER

Sponsor class

Conditions

HR+/HER2- Advanced Breast Cancer

Interventions

DRUG: Dalpiciclib
DRUG: Chidamide
DRUG: Enitinostat

Sponsor

Beijing 302 Hospital